Moteur de recherche d’entreprises européennes
UK funding (209 100 £) : Anomalies génétiques et acquises du complément dans la glomérulonéphrite membranoproliférative idiopathique Ukri01/05/2013 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Anomalies génétiques et acquises du complément dans la glomérulonéphrite membranoproliférative idiopathique
| Abstract | Idiopathic Membranoproliferative Glomerulonephritis (MPGN) is a kidney disease that predominantly affects children and young adults. It accounts for around 5% of End Stage Renal Disease (ESRD) in children. Presently, there are no specific treatments for idiopathic MPGN and consequently there is progression to ESRD requiring long term dialysis treatment. Although renal transplantation is undertaken, MPGN usually recurs in the transplant leading to graft failure. The pivotal role of the complement system in MPGN has been recognised for some time. Complement is an ancient defence system which coats both foreign cells (such as bacteria and viruses) and our own cells (including those of the kidney) with a substance called C3. This substance will eventually lead to the destruction of bacteria and viruses by damaging the cell wall. If our own cells are not protected against C3 they can suffer a similar fate. This is why we have a series of regulators which inactivate C3. We have, in pilot studies, found that patients with MPGN have mutations in and antibodies against a regulator called factor H. In this study I wish to examine whether MPGN patients have mutations in other complement genes and antibodies against other complement proteins. I will undertake this work in the Newcastle Renal Genetics Group (RGG). This research environment provides World leading expertise in the genetics of complement mediated renal disease and has access to a large database of patients with MPGN. There are now specific agents to treat both complement and antibody associated diseases. Fully characterising the underlying complement defect will allow progress towards the treatment of MPGN. The RGG has used such a strategy to yield a successful treatment for a similar complement mediated renal disease, called atypical haemolytic uraemic syndrome. We envisage similar benefits in MPGN. |
| Category | Fellowship |
| Reference | MR/K023519/1 |
| Status | Closed |
| Funded period start | 01/05/2013 |
| Funded period end | 30/04/2016 |
| Funded value | £209 100,00 |
| Source | https://gtr.ukri.org/projects?ref=MR%2FK023519%2F1 |
Participating Organisations
| Newcastle University |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : University OF Newcastle Upon Tyne CHARITY, Newcastle upon Tyne, Royaume Uni.
Les visualisations de "Newcastle University - UK funding (209 100 £) : Anomalies génétiques et acquises du complément dans la glomérulonéphrite membranoproliférative idiopathique"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
